State regulatory records reveal a concerning data point: hundreds of U.S. hospitals currently deploy Sentri7, an artificial intelligence drug monitoring platform, yet the system failed to identify systematic fentanyl diversion at a Tennessee healthcare facility over multiple months in 2025.
The detection failure is particularly significant given that the Drug Enforcement Administration estimates approximately 37,000 annual drug diversion cases in U.S. healthcare settings, with 85 percent involving healthcare workers. Current systems average six months to detect such incidents. The Sentri7 software’s inability to flag clear patterns of controlled substance theft at an operational hospital suggests potential gaps in AI validation protocols and real-world performance testing before system deployment.
This case underscores the need for healthcare institutions and regulatory bodies to rigorously assess AI surveillance tool effectiveness beyond laboratory conditions, ensuring systems deliver promised security functions before widespread adoption.
Read the full article on GMJ Newsroom.
Was this article helpful?
